|
|
||||||||||
|
J Am Coll Cardiol, 2007; 50:2218-2225, doi:10.1016/j.jacc.2007.08.032
(Published online 14 November 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,*


* Cardiac Imaging and Research Centre, Wellington Hospital, London, United Kingdom
William Harvey Research Institute at Barts and the London, Queen Marys School of Medicine and Dentistry, London, United Kingdom
Department of Endocrinology, Central Middlesex Hospital, London, United Kingdom
Stats Consultancy, London, United Kingdom
|| Department of Endocrinology, Kings College Hospital, London, United Kingdom
¶ Department of Cardiology, Royal Free Hospital, London, United Kingdom.
Manuscript received February 19, 2007; revised manuscript received August 23, 2007, accepted August 27, 2007.
* Reprint requests and correspondence: Dr. Dhakshinamurthy Vijay Anand, Cardiac Imaging and Research Centre, Wellington Hospital (South), Wellington Place, St. Johns Wood, London, NW8 9LE, United Kingdom. (Email: vdanand{at}hotmail.com).
Objectives: This study prospectively evaluated the relationship between cardiovascular risk factors, selected biomarkers (high-sensitivity C-reactive protein [hs-CRP], interleukin [IL]-6, and osteoprotegerin [OPG]), and the progression of coronary artery calcification (CAC) in type 2 diabetic subjects.
Background: Coronary artery calcification is pathognomonic of coronary atherosclerosis. Osteoprotegerin is a signaling molecule involved in bone remodeling that has been implicated in the regulation of vascular calcification and atherogenesis.
Methods: Three hundred ninety-eight type 2 diabetic subjects without prior coronary disease or symptoms (age 52 ± 8 years, 61% male, glycated hemoglobin [HbA1c] 8 ± 1.5) were evaluated serially by CAC imaging (mean follow-up 2.5 ± 0.4 years). Progression/regression of CAC was defined as a change
2.5 between the square root transformed values of baseline and follow-up volumetric CAC scores. Demographic data, risk factors, glycemic control, medication use, serum hs-CRP, IL-6, and plasma OPG levels were measured at baseline and follow-up.
Results: Two hundred eleven patients (53%) had CAC at baseline. One hundred eighteen patients (29.6%) had CAC progression, whereas 3 patients (0.8%) had regression. Age, male gender, hypertension, baseline CAC, HbA1c >7, waist-hip ratio, IL-6, OPG, use of beta-blockers, calcium channel antagonists, angiotensin-converting enzyme (ACE) inhibitors, statins, and Framingham/UKPDS (United Kingdom Prospective Diabetes Study) risk scores were univariable predictors of CAC progression. In the multivariate model, baseline CAC (odds ratio [OR] for CAC >400 = 6.38, 95% confidence interval [CI] 2.63 to 15.5, p < 0.001), HbA1c >7 (OR 1.95, CI 1.08 to 3.52, p = 0.03), and statin use (OR 2.27, CI 1.38 to 3.73, p = 0.001) were independent predictors of CAC progression.
Conclusions: Baseline CAC severity and suboptimal glycemic control are strong risk factors for CAC progression in type 2 diabetic subjects.
| ||||||||||||||
This article has been cited by other articles:
![]() |
S. J. Nicholls, E. M. Tuzcu, S. Kalidindi, K. Wolski, K.-W. Moon, I. Sipahi, P. Schoenhagen, and S. E. Nissen Effect of Diabetes on Progression of Coronary Atherosclerosis and Arterial Remodeling: A Pooled Analysis of 5 Intravascular Ultrasound Trials J. Am. Coll. Cardiol., July 22, 2008; 52(4): 255 - 262. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |